Regeneron Pharmaceuticals, Inc. (REGN)

564.23
0.77 0.14
NASDAQ
Prev Close 565.00
Open 567.48
Day Low/High 562.40 / 567.83
52 Wk Low/High 271.37 / 664.64
Volume 169.04K
Exchange NASDAQ
Shares Outstanding 106.39B
Market Cap 60.55B
P/E Ratio 22.06
Div & Yield N.A. (N.A)
Regeneron Has More Upside to Go

Regeneron Has More Upside to Go

The stock shows bullish momentum and could climb 5%.

We're Feeling Better About Growth Stocks

We're Feeling Better About Growth Stocks

Amazon is among the indicators.

Eli Lilly's Stock Is Worth a Chance Below $80

The company's stock will likely be among the first to turn.

Plenty of Good News -- If You Look

Plenty of Good News -- If You Look

Not all growth is hated today.

Drug Stocks' Earnings Power Won't Go Away

Before you sell them, ask yourself at what multiple you sell.

Regeneron downgraded at Morgan Stanley

Jim Cramer: Could Glencore Be the Next Long Term Capital?

Jim Cramer: Could Glencore Be the Next Long Term Capital?

Jim Cramer answered viewers’ Twitter (TWTR) questions from the floor of the Stock Exchange and said he's not assuaged by Glencore's (GLCNF) comments that it is ‘operationally and financially robust.'

These Biotech Trades are a Great Rx

These Biotech Trades are a Great Rx

Hillary Clinton has created some good short-term opportunities.

It May Be Early, but Check Out the Moves in These Stocks

High-growth, REIT and consumer names clearly want to go higher.

Regeneron Chart Looks Rejuvenated

Regeneron Chart Looks Rejuvenated

Shares appear ready to return to previous highs.

Not the Kind of Waves You Want to Make

Not the Kind of Waves You Want to Make

On days like this, bizarre action is the norm.

It's OK, Market: Some (But Not All) Is Forgiven

It's OK, Market: Some (But Not All) Is Forgiven

But this might be a good time to sell.

This Volatility in the Indices Is Just Plain Phony

It's just machine to machine, but we are haunted by 2008.

Build a Core Position in Biotech Intrexon at These Lower Prices

Build a Core Position in Biotech Intrexon at These Lower Prices

Following a 40% decline, now looks good for scaling into the stock.

Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage

Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage

Which means interest rate hikes are being built into prices.

Regeneron Shows a High Volume Bottom

Regeneron Shows a High Volume Bottom

Regeneron shows its relative strength in the market selloff.

How China's Troubles Affect Biotech and Pharma Stocks: Part 1

How China's Troubles Affect Biotech and Pharma Stocks: Part 1

At first glance there is little connection, but you need to look deeper.

Odds Are Regeneron Rally Can Continue

Odds Are Regeneron Rally Can Continue

My maximum risk can be defined below the July 27 low.

Finally, Respite From the Volatility

Finally, Respite From the Volatility

Still, momentum is cooling and valuation is an issue in more cases.

Stocks With Significant High Activity: the First Four Groups

Stocks With Significant High Activity: the First Four Groups

There are some good buying ideas among these stocks.

The Market Reacts Rationally for Once

High-growth names, big commodity-takers, consumer plays shine today.

You Can Run, But You Can't Hide Today

There's no such thing as a 'safe harbor' right now on Wall Street.

Jim Cramer Won't Turn on Apple, Doesn't Like Twitter Until $19.20

Jim Cramer Won't Turn on Apple, Doesn't Like Twitter Until $19.20

Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.

Futures Tick Higher; Obama Pushes Emissions Reductions

Futures Tick Higher; Obama Pushes Emissions Reductions

Coal and renewables could both react as political and legal battles ensue.

Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More

Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More

TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

When Leader Goes Down, Whole Sector Feels It

Biogen's weak numbers leave biotechs ailing.

Are Any New FANGs Baring Their Teeth?

Are Any New FANGs Baring Their Teeth?

The fearsome foursome have been reborn.

Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now

Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio

iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio

Technical factors point to a looming breakout for IBB.

Regeneron Reaches a Great Entry Point

Regeneron Reaches a Great Entry Point

This could be an opportune price to buy REGN, as it allows you to take a position fairly close to well-defined support.